| Year |
Citation |
Score |
| 2023 |
Antonarakis ES, Subudhi SK, Pieczonka CM, Karsh LI, Quinn DI, Hafron JM, Wilfehrt HM, Harmon M, Sheikh NA, Shore ND, Petrylak DP. Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 37058234 DOI: 10.1158/1078-0432.CCR-22-3832 |
0.322 |
|
| 2023 |
Siddiqui BA, Chapin BF, Jindal S, Duan F, Basu S, Yadav SS, Gu AD, Espejo AB, Kinder M, Pettaway CA, Ward JF, Tidwell RSS, Troncoso P, Corn PG, Logothetis CJ, ... ... Subudhi SK, et al. Immune and pathologic responses in patients with localized prostate cancer who received daratumumab (anti-CD38) or edicotinib (CSF-1R inhibitor). Journal For Immunotherapy of Cancer. 11. PMID 36948506 DOI: 10.1136/jitc-2022-006262 |
0.322 |
|
| 2022 |
Goswami S, Siddiqui BA, Subudhi SK, Basu S, Yadav SS, Diab A, Sharma P. A composite T cell biomarker in pre-treatment blood samples correlates with detection of immune-related adverse events. Cancer Cell. 40: 249-251. PMID 35290784 DOI: 10.1016/j.ccell.2022.02.015 |
0.336 |
|
| 2021 |
Subudhi SK, Siddiqui BA, Aparicio AM, Yadav SS, Basu S, Chen H, Jindal S, Tidwell RSS, Varma A, Logothetis CJ, Allison JP, Corn PG, Sharma P. Combined CTLA-4 and PD-L1 blockade in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer is associated with increased myeloid and neutrophil immune subsets in the bone microenvironment. Journal For Immunotherapy of Cancer. 9. PMID 34663638 DOI: 10.1136/jitc-2021-002919 |
0.314 |
|
| 2021 |
Sinha M, Zhang L, Subudhi S, Chen B, Marquez J, Liu EV, Allaire K, Cheung A, Ng S, Nguyen C, Friedlander TW, Aggarwal R, Spitzer M, Allison JP, Small EJ, et al. Pre-existing immune status associated with response to combination of sipuleucel-T and ipilimumab in patients with metastatic castration-resistant prostate cancer. Journal For Immunotherapy of Cancer. 9. PMID 33986125 DOI: 10.1136/jitc-2020-002254 |
0.377 |
|
| 2020 |
Sharma P, Pachynski RK, Narayan V, Fléchon A, Gravis G, Galsky MD, Mahammedi H, Patnaik A, Subudhi SK, Ciprotti M, Simsek B, Saci A, Hu Y, Han GC, Fizazi K. Nivolumab Plus Ipilimumab for Metastatic Castration-Resistant Prostate Cancer: Preliminary Analysis of Patients in the CheckMate 650 Trial. Cancer Cell. PMID 32916128 DOI: 10.1016/J.Ccell.2020.08.007 |
0.37 |
|
| 2020 |
Spetsieris N, Boukovala M, Weldon JA, Tsikkinis A, Hoang A, Aparicio A, Tu SM, Araujo JC, Zurita AJ, Corn PG, Pagliaro L, Kim J, Wang J, Subudhi SK, Tannir NM, et al. A Phase 2 Trial of Abiraterone Followed by Randomization to Addition of Dasatinib or Sunitinib in Men With Metastatic Castration-Resistant Prostate Cancer. Clinical Genitourinary Cancer. PMID 32675015 DOI: 10.1016/J.Clgc.2020.05.013 |
0.324 |
|
| 2020 |
Subudhi SK, Vence L, Zhao H, Blando J, Yadav SS, Xiong Q, Reuben A, Aparicio A, Corn PG, Chapin BF, Pisters LL, Troncoso P, Tidwell RS, Thall P, Wu CJ, et al. Neoantigen responses, immune correlates, and favorable outcomes after ipilimumab treatment of patients with prostate cancer. Science Translational Medicine. 12. PMID 32238575 DOI: 10.1126/Scitranslmed.Aaz3577 |
0.529 |
|
| 2020 |
Corn PG, Zhang M, Nogueras-Gonzalez GM, Xiao L, Zurita AJ, Subudhi SK, Tu SM, Aparicio AM, Coarfa C, Rajapakshe K, Huang S, Navone NM, Lin SH, Wang G, Ramachandran S, et al. A Phase II Study of Cabozantinib and Androgen Ablation in Patients with Hormone-Naïve Metastatic Prostate Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31941830 DOI: 10.1158/1078-0432.Ccr-19-2389 |
0.319 |
|
| 2020 |
Viscuse PV, Zhang M, Liu J, Slack Tidwell R, Subudhi SK, Zurita AJ, Corn PG, Tu S, Araujo JC, Wang J, Efstathiou E, Wang J, Pilie PG, Troncoso P, Zhang J, et al. Linking the Aggressive Variant Prostate Cancer (AVPC) molecular signature (-ms) to androgen indifference in a prospective clinical trial. Journal of Clinical Oncology. 38: 156-156. DOI: 10.1200/Jco.2020.38.6_Suppl.156 |
0.329 |
|
| 2020 |
Efstathiou E, Boukovala MA, Spetsieris N, Wen S, Hoang A, Weldon JA, Tidwell R, Davis JW, Chapin BF, Corn PG, Subudhi SK, Aparicio A, Pettaway CA, Pisters LL, Papadopoulos JN, et al. Neoadjuvant apalutamide (APA) plus leuprolide (LHRHa) with or without abiraterone (AA) in localized high-risk prostate cancer (LHRPC). Journal of Clinical Oncology. 38: 5504-5504. DOI: 10.1200/Jco.2020.38.15_Suppl.5504 |
0.341 |
|
| 2019 |
Jiao S, Subudhi SK, Aparicio A, Ge Z, Guan B, Miura Y, Sharma P. Differences in Tumor Microenvironment Dictate T Helper Lineage Polarization and Response to Immune Checkpoint Therapy. Cell. 179: 1177-1190.e13. PMID 31730856 DOI: 10.1016/J.Cell.2019.10.029 |
0.485 |
|
| 2019 |
Tahir SA, Gao J, Miura Y, Blando J, Tidwell RSS, Zhao H, Subudhi SK, Tawbi H, Keung E, Wargo J, Allison JP, Sharma P. Autoimmune antibodies correlate with immune checkpoint therapy-induced toxicities. Proceedings of the National Academy of Sciences of the United States of America. PMID 31611368 DOI: 10.1073/Pnas.1908079116 |
0.321 |
|
| 2019 |
Corn PG, Heath EI, Zurita A, Ramesh N, Xiao L, Sei E, Li-Ning-Tapia E, Tu SM, Subudhi SK, Wang J, Wang X, Efstathiou E, Thompson TC, Troncoso P, Navin N, et al. Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1-2 trial. The Lancet. Oncology. PMID 31515154 DOI: 10.1016/S1470-2045(19)30408-5 |
0.318 |
|
| 2019 |
Vence L, Bucktrout SL, Fernandez Curbelo I, Blando J, Smith BM, Mahne AE, Lin JC, Park T, Pascua E, Chaparro-Riggers J, Subudhi SK, Borin Scutti J, Higa MG, Zhao H, Yadav SS, et al. Characterization and comparison of GITR expression in solid tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31358539 DOI: 10.1158/1078-0432.Ccr-19-0289 |
0.333 |
|
| 2019 |
Abu-Sbeih H, Ali FS, Naqash AR, Owen DH, Patel S, Otterson GA, Kendra K, Ricciuti B, Chiari R, De Giglio A, Sleiman J, Funchain P, Wills B, Zhang J, Naidoo J, ... ... Subudhi SK, et al. Resumption of Immune Checkpoint Inhibitor Therapy After Immune-Mediated Colitis. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1900320. PMID 31163011 DOI: 10.1200/Jco.19.00320 |
0.313 |
|
| 2019 |
Sharma A, Subudhi SK, Blando J, Vence L, Wargo J, Allison JP, Ribas A, Sharma P. Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3 Regulatory T Cells (Tregs) in Human Cancers-Response. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 25: 3469-3470. PMID 31160495 DOI: 10.1158/1078-0432.CCR-19-0402 |
0.397 |
|
| 2019 |
Sharma P, Pachynski RK, Narayan V, Flechon A, Gravis G, Galsky MD, Mahammedi H, Patnaik A, Subudhi SK, Ciprotti M, Duan T, Saci A, Hu S, Han GC, Fizazi K. Initial results from a phase II study of nivolumab (NIVO) plus ipilimumab (IPI) for the treatment of metastatic castration-resistant prostate cancer (mCRPC; CheckMate 650). Journal of Clinical Oncology. 37: 142-142. DOI: 10.1200/Jco.2019.37.7_Suppl.142 |
0.334 |
|
| 2019 |
Subudhi SK, Aparicio A, Zurita AJ, Doger B, Kelly WK, Peer A, Rathkopf DE, Karsh LI, Tryon JJ, Kothari N, Zhao X, Zhu E, Ricci DS, Tran N, De Bono JS. A phase Ib/II study of niraparib combination therapies for the treatment of metastatic castration-resistant prostate cancer (NCT03431350). Journal of Clinical Oncology. 37: TPS5087-TPS5087. DOI: 10.1200/Jco.2019.37.15_Suppl.Tps5087 |
0.351 |
|
| 2019 |
Drake CG, Pachynski RK, Subudhi SK, McNeel DG, Antonarakis ES, Bauer TM, Patricia D, Wade M, Zudaire E, Mason G, Knoblauch RE, Stone NL, Infante JR, Gottardis M, Fong L. Safety and preliminary immunogenicity of JNJ-64041809, a live attenuated, double-deleted Listeria monocytogenes-based immunotherapy, in metastatic castration-resistant prostate cancer (mCRPC). Journal of Clinical Oncology. 37: e16509-e16509. DOI: 10.1200/Jco.2019.37.15_Suppl.E16509 |
0.373 |
|
| 2019 |
Siddiqui BA, Durand J, Gao J, Wang J, Aparicio A, Campbell MT, Siefker-Radtke AO, Tannir NM, Corn PG, Msaouel P, Shah AY, Zurita AJ, Tu S, Suarez-Almazor ME, Sudhakar T, ... ... Subudhi SK, et al. Clinical and immunological analyses of immune checkpoint inhibitor-associated neuromuscular (NM) toxicities. Journal of Clinical Oncology. 37: e14118-e14118. DOI: 10.1200/Jco.2019.37.15_Suppl.E14118 |
0.325 |
|
| 2019 |
Chapin BF, Wang X, Zhang M, Corn PG, Zurita AJ, Elsheshtawi MA, Davis JW, Pettaway CA, Adibi M, Gleave M, Cooperberg MR, Smaldone MC, Mcguire SE, Tu S, Wang J, ... Subudhi SK, et al. Complex biologic heterogeneity of de novo hormone naïve metastatic prostate cancer (HNPCa): Comparison of early progressors and prolonged responders to initial systemic treatment. Journal of Clinical Oncology. 37: 5055-5055. DOI: 10.1200/Jco.2019.37.15_Suppl.5055 |
0.319 |
|
| 2019 |
Aparicio A, Zhang M, Ramesh N, Wang X, Corn PG, Zurita AJ, Davis JW, Pettaway CA, Adibi M, Mcguire SE, Tu S, Wang J, Subudhi SK, Elsheshtawi MA, Efstathiou E, et al. Aggressive variant prostate cancer (AVPC) molecular signature in castration-sensitive, de novo metastatic prostate cancer (M1PCa). Journal of Clinical Oncology. 37: 5052-5052. DOI: 10.1200/Jco.2019.37.15_Suppl.5052 |
0.339 |
|
| 2019 |
Tran B, Kouros-Mehr H, Fermin A, Horvath L, Roncolato F, Rettig M, Dorff T, Tagawa S, Subudhi S, Antonarakis E, Armstrong A, Petrylak D, Fizazi K, Salvati M, Scher H. A phase I study of AMG 160, a half-life extended bispecific T cell engager (HLE BiTE) immuno-oncology therapy targeting PSMA, in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) Annals of Oncology. 30: v353. DOI: 10.1093/Annonc/Mdz248.052 |
0.412 |
|
| 2018 |
Wang Y, Wiesnoski DH, Helmink BA, Gopalakrishnan V, Choi K, DuPont HL, Jiang ZD, Abu-Sbeih H, Sanchez CA, Chang CC, Parra ER, Francisco-Cruz A, Raju GS, Stroehlein JR, Campbell MT, ... ... Subudhi SK, et al. Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis. Nature Medicine. PMID 30420754 DOI: 10.1038/S41591-018-0238-9 |
0.353 |
|
| 2018 |
Choi K, Abu-Sbeih H, Samdani R, Nogueras Gonzalez G, Raju GS, Richards DM, Gao J, Subudhi S, Stroehlein J, Wang Y. Can Immune Checkpoint Inhibitors Induce Microscopic Colitis or a Brand New Entity? Inflammatory Bowel Diseases. PMID 30169584 DOI: 10.1093/Ibd/Izy240 |
0.301 |
|
| 2018 |
Sharma A, Subudhi SK, Blando J, Scutti J, Vence L, Wargo JA, Allison JP, Ribas A, Sharma P. Anti-CTLA-4 immunotherapy does not deplete FOXP3+ regulatory T cells (Tregs) in human cancers. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30054281 DOI: 10.1158/1078-0432.Ccr-18-0762 |
0.508 |
|
| 2018 |
Goswami S, Apostolou I, Zhang J, Skepner J, Anandhan S, Zhang X, Xiong L, Trojer P, Aparicio A, Subudhi SK, Allison JP, Zhao H, Sharma P. Modulation of EZH2 expression in T cells improves efficacy of anti-CTLA-4 therapy. The Journal of Clinical Investigation. PMID 29905573 DOI: 10.1172/Jci99760 |
0.551 |
|
| 2017 |
Bilen MA, Hess KR, Subudhi SK, Aparicio A, Kim J, Zurita-Saavedra AJ, Araujo JC, Corn PG, Stover J, Lin SH, Logothetis CJ, Tu SM. Clinical predictors of survival in patients with castration-resistant prostate cancer receiving sipuleucel-T cellular immunotherapy. Cancer Chemotherapy and Pharmacology. PMID 28730293 DOI: 10.1007/S00280-017-3391-9 |
0.407 |
|
| 2017 |
Gao J, Ward JF, Pettaway CA, Shi LZ, Subudhi SK, Vence LM, Zhao H, Chen J, Chen H, Efstathiou E, Troncoso P, Allison JP, Logothetis CJ, Wistuba II, Sepulveda MA, et al. VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer. Nature Medicine. PMID 28346412 DOI: 10.1038/Nm.4308 |
0.365 |
|
| 2017 |
Corn PG, Zurita AJ, Subudhi SK, Tu S, Aparicio A, Araujo JC, Kim J, Wang J, Efstathiou E, Pagliaro LC, Logothetis C. Cabozantinib plus androgen deprivation therapy in patients with androgen-dependent metastatic prostate cancer. Journal of Clinical Oncology. 35: 169-169. DOI: 10.1200/Jco.2017.35.6_Suppl.169 |
0.338 |
|
| 2017 |
Gao J, Ward JF, Pettaway CA, Shi LZ, Subudhi SK, Vence LM, Zhao H, Chen J, Chen H, Efstathiou E, Troncoso P, Allison JP, Logothetis C, Wistuba II, Wargo JA, et al. Investigation of mechanisms of resistance to ipilimumab therapy with a pre-surgical trial in patients with high-risk, localized prostate cancer. Journal of Clinical Oncology. 35: 5081-5081. DOI: 10.1200/Jco.2017.35.15_Suppl.5081 |
0.42 |
|
| 2017 |
Subudhi SK, Aparicio A, Troncoso P, Zhang J, Gumbs C, Wu C, Gao J, Vence LM, Blando JM, Corn PG, Araujo JC, Zurita AJ, Prokhorova IN, Van Alstine M, Logothetis C, et al. Linking tumor mutational load to clinical responses to ipilimumab (IPI) in men with advanced prostate cancer (PCa). Journal of Clinical Oncology. 35: 5065-5065. DOI: 10.1200/Jco.2017.35.15_Suppl.5065 |
0.347 |
|
| 2016 |
Subudhi SK, Aparicio A, Gao J, Zurita AJ, Araujo JC, Logothetis CJ, Tahir SA, Korivi BR, Slack RS, Vence L, Emerson RO, Yusko E, Vignali M, Robins HS, Sun J, et al. Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities. Proceedings of the National Academy of Sciences of the United States of America. PMID 27698113 DOI: 10.1073/Pnas.1611421113 |
0.519 |
|
| 2016 |
Miyahira AK, Roychowdhury S, Goswami S, Ippolito JE, Priceman SJ, Pritchard CC, Sfanos KS, Subudhi SK, Simons JW, Pienta KJ, Soule HR. Beyond Seed and Soil: Understanding and Targeting Metastatic Prostate Cancer; Report From the 2016 Coffey-Holden Prostate Cancer Academy Meeting. The Prostate. PMID 27679977 DOI: 10.1002/Pros.23260 |
0.307 |
|
| 2016 |
Shi LZ, Fu T, Guan B, Chen J, Blando JM, Allison JP, Xiong L, Subudhi SK, Gao J, Sharma P. Interdependent IL-7 and IFN-γ signalling in T-cell controls tumour eradication by combined α-CTLA-4+α-PD-1 therapy. Nature Communications. 7: 12335. PMID 27498556 DOI: 10.1038/Ncomms12335 |
0.367 |
|
| 2016 |
Bilen MA, Subudhi SK, Gao J, Tannir NM, Tu SM, Sharma P. Acute rhabdomyolysis with severe polymyositis following ipilimumab-nivolumab treatment in a cancer patient with elevated anti-striated muscle antibody. Journal For Immunotherapy of Cancer. 4: 36. PMID 27330809 DOI: 10.1186/S40425-016-0139-8 |
0.406 |
|
| 2016 |
Goswami S, Aparicio A, Subudhi SK. Immune Checkpoint Therapies in Prostate Cancer. Cancer Journal (Sudbury, Mass.). 22: 117-20. PMID 27111907 DOI: 10.1097/Ppo.0000000000000176 |
0.365 |
|
| 2016 |
Subudhi SK, Aparicio A, Troncoso P, Zhang J, Gumbs C, Wu C, Vence LM, Logothetis C, Futreal A, Allison JP, Sharma P. A feasibility study to determine T cell responses to neoantigens following treatment with ipilimumab in men with metastatic castration-resistant prostate carcinoma (mCRPC). Journal of Clinical Oncology. 34: e14506-e14506. DOI: 10.1200/Jco.2016.34.15_Suppl.E14506 |
0.44 |
|
| 2016 |
Subudhi SK, Aparicio A, Gao J, Zurita-Saavedra A, Araujo JC, Logothetis CJ, Brinda KR, Allison JP, Vence L, Emerson RO, Yusko E, Vignali M, Robins HS, Sun J, Sharma P. Abstract 1402: Exploratory biomarkers that predict for clinical outcomes in a Phase II trial with ipilimumab plus finite androgen deprivation therapy for metastatic non-castrate prostate cancer Cancer Research. 76: 1402-1402. DOI: 10.1158/1538-7445.Am2016-1402 |
0.409 |
|
| 2015 |
Gao J, He Q, Subudhi S, Aparicio A, Zurita-Saavedra A, Lee DH, Jimenez C, Suarez-Almazor M, Sharma P. Review of immune-related adverse events in prostate cancer patients treated with ipilimumab: MD Anderson experience. Oncogene. PMID 25659583 DOI: 10.1038/Onc.2015.5 |
0.331 |
|
| 2015 |
Chapin BF, Mcguire SE, Wang X, Troncoso P, Davis JW, Navai N, Subudhi SK, Zurita AJ, Araujo JC, Pettaway CA, Matin SF, Pisters LL, Ward JF, Tu S, Wang J, et al. A prospective, multicenter, randomized phase II trial of best systemic therapy (BST) or BST plus definitive treatment (Surgery or Radiation) of the primary tumor in metastatic prostate cancer. Journal of Clinical Oncology. 33: TPS5075-TPS5075. DOI: 10.1200/Jco.2015.33.15_Suppl.Tps5075 |
0.328 |
|
| 2015 |
Corn PG, Tu S, Zurita AJ, Subudhi SK, Araujo JC, Kim J, Jonasch E, Pagliaro LC, Siefker-Radtke AO, Wang J, Wang X, Heath EI, Logothetis C, Aparicio A. A multi-institutional randomized phase II study (NCT01505868) of cabazitaxel (CAB) plus or minus carboplatin (CARB) in men with metastatic castration-resistant prostate cancer (mCRPC). Journal of Clinical Oncology. 33: 5010-5010. DOI: 10.1200/Jco.2015.33.15_Suppl.5010 |
0.336 |
|
| 2015 |
Subudhi SK, Aparicio A, Gao J, Zurita A, John A, Logothetis C, Rao B, Vence L, Allison J, Emerson RO, Yusko E, Vignali M, Robins H, Sun JJ, Sharma P. Immune correlates in a Phase II clinical trial with ipilimumab in combination with finite androgen deprivation therapy in patients with metastatic non-castrate prostate cancer Journal For Immunotherapy of Cancer. 3. DOI: 10.1186/2051-1426-3-S2-P106 |
0.333 |
|
| 2014 |
Subudhi SK, Aparicio A, Zurita AJ, Araujo JC, Corn PG, Tu S, Wang X, Harris DR, Winslow KA, Gao J, Logothetis CJ, Sharma P. 1053PDFINITE ANDROGEN DEPRIVATION THERAPY (ADT) PLUS IPILIMUMAB (IPI) IN MEN WITH HORMONE-NAïVE METASTATIC PROSTATE CANCER (HN-MPCA). Annals of Oncology : Official Journal of the European Society For Medical Oncology. 25: iv363. PMID 28171240 DOI: 10.1093/Annonc/Mdu342.6 |
0.466 |
|
| 2014 |
Zamarin D, Holmgaard RB, Subudhi SK, Park JS, Mansour M, Palese P, Merghoub T, Wolchok JD, Allison JP. Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. Science Translational Medicine. 6: 226ra32. PMID 24598590 DOI: 10.1126/Scitranslmed.3008095 |
0.405 |
|
| 2014 |
Zamarin D, Holmgaard RB, Subudhi SK, Park J, Mansour M, Palese P, Merghoub T, Wolchok JD, Allison JP. Potentiation of immune checkpoint blockade cancer immunotherapy with oncolytic virus. Journal of Clinical Oncology. 32: 3051-3051. DOI: 10.1200/Jco.2014.32.15_Suppl.3051 |
0.374 |
|
| 2013 |
Arora VK, Schenkein E, Murali R, Subudhi SK, Wongvipat J, Balbas MD, Shah N, Cai L, Efstathiou E, Logothetis C, Zheng D, Sawyers CL. Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade. Cell. 155: 1309-22. PMID 24315100 DOI: 10.1016/J.Cell.2013.11.012 |
0.346 |
|
| 2013 |
Reis BS, Jungbluth AA, Frosina D, Holz M, Ritter E, Nakayama E, Ishida T, Obata Y, Carver B, Scher H, Scardino PT, Slovin S, Subudhi SK, Reuter VE, Savage C, et al. Prostate cancer progression correlates with increased humoral immune response to a human endogenous retrovirus GAG protein. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 6112-25. PMID 24081977 DOI: 10.1158/1078-0432.Ccr-12-3580 |
0.342 |
|
| 2013 |
Zamarin D, Holmgaard R, Subudhi S, Mansour M, Palese P, Merghoub T, Wolchok JD, Allison JP. Localized oncolytic virotherapy inflames distant tumors and synergizes with immune checkpoint blockade leading to systemic tumor rejection Journal For Immunotherapy of Cancer. 1. DOI: 10.1186/2051-1426-1-S1-O9 |
0.411 |
|
| 2012 |
Oh WK, Kantoff P, Scher HI, Magidson J, Wassmann K, Lee GM, Katz LM, Subudhi SK, Anand A, Fleisher M, Galsky MD, Ross RW. A validated whole-blood RNA transcript-based prognostic model that predicts survival in men with castration-resistant prostate cancer. Journal of Clinical Oncology. 30: 4516-4516. DOI: 10.1200/Jco.2012.30.15_Suppl.4516 |
0.325 |
|
| 2011 |
Subudhi SK, Heller G, Anand A, Danila DC, Fleisher M, Scher HI. A six-gene panel that predicts survival in men with castration-resistant prostate cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 4539. PMID 28023419 DOI: 10.1200/Jco.2011.29.15_Suppl.4539 |
0.339 |
|
| 2005 |
Anders RA, Subudhi SK, Wang J, Pfeffer K, Fu YX. Contribution of the lymphotoxin beta receptor to liver regeneration. Journal of Immunology (Baltimore, Md. : 1950). 175: 1295-300. PMID 16002734 DOI: 10.4049/Jimmunol.175.2.1295 |
0.536 |
|
| 2005 |
Wang Y, Subudhi SK, Anders RA, Lo J, Sun Y, Blink S, Wang Y, Wang J, Liu X, Mink K, Degrandi D, Pfeffer K, Fu YX. The role of herpesvirus entry mediator as a negative regulator of T cell-mediated responses. The Journal of Clinical Investigation. 115: 711-7. PMID 15696194 DOI: 10.1172/JCI22982 |
0.729 |
|
| 2005 |
Subudhi SK, Alegre ML, Fu YX. The balance of immune responses: costimulation verse coinhibition. Journal of Molecular Medicine (Berlin, Germany). 83: 193-202. PMID 15630593 DOI: 10.1007/S00109-004-0617-1 |
0.58 |
|
| 2005 |
Wang Y, Subudhi SK, Anders RA, Lo J, Sun Y, Blink S, Wang Y, Wang J, Liu X, Mink K, Degrandi D, Pfeffer K, Fu YX. The role of herpesvirus entry mediator as a negative regulator of T cell–mediated responses Journal of Clinical Investigation. 115: 711-717. DOI: 10.1172/Jci200522982 |
0.74 |
|
| 2004 |
Baron BW, Anastasi J, Montag A, Huo D, Baron RM, Karrison T, Thirman MJ, Subudhi SK, Chin RK, Felsher DW, Fu YX, McKeithan TW, Baron JM. The human BCL6 transgene promotes the development of lymphomas in the mouse. Proceedings of the National Academy of Sciences of the United States of America. 101: 14198-203. PMID 15375218 DOI: 10.1073/Pnas.0406138101 |
0.689 |
|
| 2004 |
Subudhi SK, Zhou P, Yerian LM, Chin RK, Lo JC, Anders RA, Sun Y, Chen L, Wang Y, Alegre ML, Fu YX. Local expression of B7-H1 promotes organ-specific autoimmunity and transplant rejection. The Journal of Clinical Investigation. 113: 694-700. PMID 14991067 DOI: 10.1172/Jci19210 |
0.733 |
|
| 2003 |
Sun Y, Subudhi SK, Fu YX. Co-stimulation agonists as a new immunotherapy for autoimmune diseases. Trends in Molecular Medicine. 9: 483-9. PMID 14604826 DOI: 10.1016/J.Molmed.2003.09.011 |
0.607 |
|
| 2003 |
Tang Q, Henriksen KJ, Boden EK, Tooley AJ, Ye J, Subudhi SK, Zheng XX, Strom TB, Bluestone JA. Cutting edge: CD28 controls peripheral homeostasis of CD4+CD25+ regulatory T cells. Journal of Immunology (Baltimore, Md. : 1950). 171: 3348-52. PMID 14500627 DOI: 10.4049/Jimmunol.171.7.3348 |
0.338 |
|
| 2002 |
Sun Y, Chen HM, Subudhi SK, Chen J, Koka R, Chen L, Fu YX. Costimulatory molecule-targeted antibody therapy of a spontaneous autoimmune disease. Nature Medicine. 8: 1405-13. PMID 12426559 DOI: 10.1038/Nm1202-796 |
0.598 |
|
| 2002 |
Tang Q, Subudhi SK, Henriksen KJ, Long CG, Vives F, Bluestone JA. The Src family kinase Fyn mediates signals induced by TCR antagonists. Journal of Immunology (Baltimore, Md. : 1950). 168: 4480-7. PMID 11970992 DOI: 10.4049/Jimmunol.168.9.4480 |
0.417 |
|
| 2002 |
Sun Y, Lin X, Chen HM, Wu Q, Subudhi SK, Chen L, Fu YX. Administration of agonistic anti-4-1BB monoclonal antibody leads to the amelioration of experimental autoimmune encephalomyelitis. Journal of Immunology (Baltimore, Md. : 1950). 168: 1457-65. PMID 11801689 DOI: 10.4049/Jimmunol.168.3.1457 |
0.663 |
|
| 2001 |
Tesciuba AG, Subudhi S, Rother RP, Faas SJ, Frantz AM, Elliot D, Weinstock J, Matis LA, Bluestone JA, Sperling AI. Inducible costimulator regulates Th2-mediated inflammation, but not Th2 differentiation, in a model of allergic airway disease. Journal of Immunology (Baltimore, Md. : 1950). 167: 1996-2003. PMID 11489981 DOI: 10.4049/Jimmunol.167.4.1996 |
0.387 |
|
| Low-probability matches (unlikely to be authored by this person) |
| 2018 |
Efstathiou E, Wang X, Zurita AJ, Tu S, Aparicio A, Wang J, Corn PG, Subudhi SK, Araujo JC, Reece LK, Pruitt L, Vanalstine ML, Logothetis C. A randomized study of finite abiraterone acetate (AA) plus leuprolide (LHRHa) versus LHRHa in biochemically recurrent non metastatic hormone naïve prostate cancer (M0HNPC). Journal of Clinical Oncology. 36: 5002-5002. DOI: 10.1200/Jco.2018.36.15_Suppl.5002 |
0.299 |
|
| 2018 |
Corn PG, Subudhi SK, Araujo JC, Vardaki I, Aparicio A, Tu S, Pagliaro LC, Zurita AJ, Logothetis C, Panaretakis T. Molecular profiling of liquid biopsies from patients (pts) with bone metastatic castration-resistant prostate cancer (BM-CRPC) treated with radium-223 (RA-223) to reveal differential enrichment for markers that correlate with overall survival (OS). Journal of Clinical Oncology. 36: 259-259. DOI: 10.1200/Jco.2018.36.6_Suppl.259 |
0.297 |
|
| 2012 |
Ross RW, Galsky MD, Scher HI, Magidson J, Wassmann K, Lee GS, Katz L, Subudhi SK, Anand A, Fleisher M, Kantoff PW, Oh WK. A whole-blood RNA transcript-based prognostic model in men with castration-resistant prostate cancer: a prospective study. The Lancet. Oncology. 13: 1105-13. PMID 23059047 DOI: 10.1016/S1470-2045(12)70263-2 |
0.297 |
|
| 2016 |
Odisio BC, Christensen JA, Subudhi SK, Huang S, Gupta S, Ahrar K, Sheth R, Ensor J, Aparicio A. Image guided thermal ablation of prostate cancer metastases to the liver. Journal of Clinical Oncology. 34: e16515-e16515. DOI: 10.1200/Jco.2016.34.15_Suppl.E16515 |
0.296 |
|
| 2013 |
Subudhi SK, Heller G, Danila DC, Anand A, Lacuna KP, Samoila A, Fleisher M, Scher HI. Sera cytokine levels to predict survival in men with progressive castration-resistant prostate cancer. Journal of Clinical Oncology. 31: 5083-5083. DOI: 10.1200/Jco.2013.31.15_Suppl.5083 |
0.295 |
|
| 2018 |
Iyer PC, Cabanillas M, Waguespack SG, Hu MI, Thosani SN, Lavis VR, Busaidy N, Subudhi SK, Diab A, Dadu R. Immune Checkpoint Inhibitor mediated Thyroiditis. Thyroid : Official Journal of the American Thyroid Association. PMID 30132401 DOI: 10.1089/Thy.2018.0116 |
0.29 |
|
| 2019 |
Abu-Sbeih H, Ali F, Naqash AR, Owen DH, Patel SH, Otterson GA, Kendra KL, Ricciuti B, Chiari R, Giglio AD, Sleiman J, Funchain P, Beatriz W, Zhang J, Naidoo J, ... ... Subudhi SK, et al. Immune-mediated colitis after resumption of immune checkpoint inhibitor therapy. Journal of Clinical Oncology. 37: 2577-2577. DOI: 10.1200/Jco.2019.37.15_Suppl.2577 |
0.288 |
|
| 2011 |
Callahan MK, Yang A, Tandon S, Xu Y, Subudhi SK, Roman RA, Heine AI, Pogoriler E, Kuk D, Panageas K, Yuan JD, Allison JP, Wolchok JD. Evaluation of serum IL-17 levels during ipilimumab therapy: Correlation with colitis. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 2505. PMID 28022388 DOI: 10.1200/Jco.2011.29.15_Suppl.2505 |
0.288 |
|
| 2017 |
Özdemir BC, Siefker-Radtke AO, Campbell MT, Subudhi SK. Current and Future Applications of Novel Immunotherapies in Urological Oncology: A Critical Review of the Literature. European Urology Focus. PMID 29056275 DOI: 10.1016/J.Euf.2017.10.001 |
0.279 |
|
| 2012 |
Curran MA, Callahan MK, Subudhi SK, Allison JP. Response to "Ipilimumab (Yervoy) and the TGN1412 catastrophe". Immunobiology. 217: 590-2. PMID 22459268 DOI: 10.1016/J.Imbio.2011.11.001 |
0.277 |
|
| 2020 |
Cable J, Greenbaum B, Pe'er D, Bollard CM, Bruni S, Griffin ME, Allison JP, Wu CJ, Subudhi SK, Mardis ER, Brentjens R, Sosman JA, Cemerski S, Zavitsanou AM, Proia T, et al. Frontiers in cancer immunotherapy-a symposium report. Annals of the New York Academy of Sciences. PMID 33184911 DOI: 10.1111/nyas.14526 |
0.269 |
|
| 2018 |
Sheth RA, Perkons N, Dondossola E, Subudhi SK, Gade TP, Tam AL. Patient-Derived Xenograft Tumor Models: Overview and Relevance to IR. Journal of Vascular and Interventional Radiology : Jvir. 29: 880-882.e1. PMID 29798759 DOI: 10.1016/J.Jvir.2018.01.782 |
0.252 |
|
| 2023 |
Sharma P, Goswami S, Raychaudhuri D, Siddiqui BA, Singh P, Nagarajan A, Liu J, Subudhi SK, Poon C, Gant KL, Herbrich SM, Anandhan S, Islam S, Amit M, Anandappa G, et al. Immune checkpoint therapy-current perspectives and future directions. Cell. 186: 1652-1669. PMID 37059068 DOI: 10.1016/j.cell.2023.03.006 |
0.249 |
|
| 2020 |
Shannon VR, Subudhi SK, Huo L, Faiz SA. Diffuse alveolar hemorrhage with nivolumab monotherapy. Respiratory Medicine Case Reports. 30: 101131. PMID 32577370 DOI: 10.1016/J.Rmcr.2020.101131 |
0.248 |
|
| 2017 |
Laccetti AL, Subudhi SK. Immunotherapy for metastatic prostate cancer: immuno-cold or the tip of the iceberg? Current Opinion in Urology. PMID 28825923 DOI: 10.1097/MOU.0000000000000433 |
0.247 |
|
| 2021 |
Chang KY, Chiang NJ, Wu SY, Yen CJ, Chen SH, Yeh YM, Li CF, Feng X, Wu K, Johnston A, Bomalaski JS, Wu BW, Gao J, Subudhi SK, Kaseb AO, et al. Phase 1b study of pegylated arginine deiminase (ADI-PEG 20) plus Pembrolizumab in advanced solid cancers. Oncoimmunology. 10: 1943253. PMID 34290906 DOI: 10.1080/2162402X.2021.1943253 |
0.247 |
|
| 2021 |
Sharma P, Siddiqui BA, Anandhan S, Yadav SS, Subudhi SK, Gao J, Goswami S, Allison JP. The Next Decade of Immune Checkpoint Therapy. Cancer Discovery. 11: 838-857. PMID 33811120 DOI: 10.1158/2159-8290.CD-20-1680 |
0.242 |
|
| 2021 |
Siddiqui BA, Gheeya JS, Goswamy R, Bathala TK, Surasi DS, Gao J, Shah A, Campbell MT, Msaouel P, Goswami S, Wang J, Zurita AJ, Jonasch E, Corn PG, Aparicio AM, ... ... Subudhi SK, et al. Durable responses in patients with genitourinary cancers following immune checkpoint therapy rechallenge after moderate-to-severe immune-related adverse events. Journal For Immunotherapy of Cancer. 9. PMID 34326169 DOI: 10.1136/jitc-2021-002850 |
0.241 |
|
| 2020 |
Kim ST, Murphy WA, Aparicio A, Subudhi SK. RS3PE Following Treatment With Combination of Hormonal Therapies Plus Ipilimumab in a Patient With Metastatic Prostate Cancer. Journal of Immunotherapy and Precision Oncology. 3: 128-132. PMID 35663254 DOI: 10.36401/JIPO-20-2 |
0.237 |
|
| 2018 |
Wang Y, Wiesnoski DH, Helmink BA, Gopalakrishnan V, Choi K, DuPont HL, Jiang ZD, Abu-Sbeih H, Sanchez CA, Chang CC, Parra ER, Francisco-Cruz A, Raju GS, Stroehlein JR, Campbell MT, ... ... Subudhi SK, et al. Author Correction: Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis. Nature Medicine. PMID 30479380 DOI: 10.1038/S41591-018-0305-2 |
0.235 |
|
| 2000 |
Cassel DL, Subudhi SK, Surrey S, McKenzie SE. GATA and NF-Y participate in transcriptional regulation of FcγRIIA in megakaryocytic cells Blood Cells, Molecules, and Diseases. 26: 587-597. PMID 11112392 DOI: 10.1006/Bcmd.2000.0337 |
0.208 |
|
| 2021 |
Vardaki I, Corn P, Gentile E, Song JH, Madan N, Hoang A, Parikh NU, Guerra LD, Lee YC, Lin SC, Yu G, Santos E, Melancon M, Troncoso P, Navone NM, ... ... Subudhi SK, et al. Radium 223 treatment increase immune checkpoint expression in extracellular vesicles from the metastatic prostate cancer bone microenvironment. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 33753455 DOI: 10.1158/1078-0432.CCR-20-4790 |
0.205 |
|
| 2021 |
Drake CG, Pachynski RK, Subudhi SK, McNeel DG, Antonarakis ES, Bauer TM, Lauer P, Brockstedt D, Patricia D, Wade M, Zudaire E, Bandyopadhyay N, Parasrampuria DA, Girgis S, Mason GE, et al. Safety and preliminary immunogenicity of JNJ-64041809, a live-attenuated, double-deleted Listeria monocytogenes-based immunotherapy, in metastatic castration-resistant prostate cancer. Prostate Cancer and Prostatic Diseases. PMID 34257408 DOI: 10.1038/s41391-021-00402-8 |
0.197 |
|
| 2022 |
Siddiqui BA, Subudhi SK, Sharma P. Anti-PD-L1 plus enzalutamide does not improve overall survival in prostate cancer. Cell Reports. Medicine. 3: 100613. PMID 35492243 DOI: 10.1016/j.xcrm.2022.100613 |
0.196 |
|
| 2020 |
Boukovala M, Spetsieris N, Weldon JA, Tsikkinis A, Hoang A, Aparicio A, Tu SM, Araujo JC, Zurita AJ, Corn PG, Pagliaro L, Kim J, Wang J, Subudhi SK, Tannir NM, et al. A candidate androgen signalling signature predictive of response to abiraterone acetate in men with metastatic castration-resistant prostate cancer. European Journal of Cancer (Oxford, England : 1990). 127: 67-75. PMID 31986451 DOI: 10.1016/j.ejca.2019.12.027 |
0.192 |
|
| 2024 |
Anselmino N, Labanca E, Shepherd PDA, Dong J, Yang J, Song X, Nandakumar S, Kundra R, Lee CJ, Schultz N, Zhang J, Araujo JC, Aparicio AM, Subudhi SK, Corn PG, et al. Integrative molecular analyses of the MD Anderson prostate cancer patient-derived xenograft (MDA PCa PDX) series. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 38488813 DOI: 10.1158/1078-0432.CCR-23-2438 |
0.184 |
|
| 2021 |
Spetsieris N, Boukovala M, Alafis I, Davis J, Zurita A, Wang X, Tu SM, Chapin BF, Aparicio A, Corn P, Wang J, Subudhi SK, Araujo J, Papadopoulos J, Pruitt L, et al. Abiraterone acetate plus prednisone in non-metastatic biochemically recurrent castration-naïve prostate cancer. European Journal of Cancer (Oxford, England : 1990). 157: 259-267. PMID 34536949 DOI: 10.1016/j.ejca.2021.06.017 |
0.184 |
|
| 2024 |
Fayle SE, Palaskas NL, Siddiqui BA, McQuade JL, Lin JS, Subudhi SK, Patel AB, Jenq RR, Shah AY, Spelman AR, Sun M, Marble BH, Wang Y. Development of a Strategic Initiative at MD Anderson Cancer Center to Improve Outcomes in Immune-Related Adverse Events. Journal of the National Comprehensive Cancer Network : Jnccn. 1-8. PMID 38190801 DOI: 10.6004/jnccn.2023.7119 |
0.181 |
|
| 2024 |
Aparicio AM, Tidwell RSS, Yadav SS, Chen JS, Zhang M, Liu J, Guo S, Pilie PG, Yu Y, Song X, Vundavilli H, Jindal S, Zhu K, Viscuse PV, Lebenthal JM, ... ... Subudhi SK, et al. A Modular Trial of Androgen Signaling Inhibitor Combinations Testing a Risk-Adapted Strategy in Patients with Metastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 38683200 DOI: 10.1158/1078-0432.CCR-23-3740 |
0.174 |
|
| 2021 |
Palaskas NL, Segura A, Lelenwa L, Siddiqui BA, Subudhi SK, Lopez-Mattei J, Durand JB, Deswal A, Zhao B, Maximilian Buja L, Iliescu C. Immune checkpoint inhibitor myocarditis: elucidating the spectrum of disease through endomyocardial biopsy. European Journal of Heart Failure. PMID 34114291 DOI: 10.1002/ejhf.2265 |
0.173 |
|
| 2023 |
Hahn AW, Thoman W, Koutroumpakis E, Abdulla A, Subudhi SK, Aparicio A, Basen-Enngquist K, Logothetis CJ, Gilchrist SC. Cardiometabolic healthcare for men with prostate cancer: an MD Anderson Cancer Center experience. Cardio-Oncology (London, England). 9: 33. PMID 37705024 DOI: 10.1186/s40959-023-00186-x |
0.168 |
|
| 2019 |
Subudhi SK. New approaches to immunotherapy for metastatic castration-resistant prostate cancer. Clinical Advances in Hematology & Oncology : H&O. 17: 283-286. PMID 31188806 |
0.163 |
|
| 2021 |
Msaouel P, Oromendia C, Siefker-Radtke AO, Tannir NM, Subudhi SK, Gao J, Wang Y, Siddiqui BA, Shah AY, Aparicio AM, Campbell MT, Zurita AJ, Shaw LK, Lopez LP, McCord H, et al. Evaluation of Technology-Enabled Monitoring of Patient-Reported Outcomes to Detect and Treat Toxic Effects Linked to Immune Checkpoint Inhibitors. Jama Network Open. 4: e2122998. PMID 34459906 DOI: 10.1001/jamanetworkopen.2021.22998 |
0.161 |
|
| 2023 |
Viscuse PV, Slack-Tidwell RS, Zhang M, Rohra P, Zhu K, San Lucas FA, Konnick E, Pilie PG, Siddiqui B, Logothetis CJ, Corn P, Subudhi SK, Pritchard CC, Soundararajan R, Aparicio A. Evaluation of the Aggressive-Variant Prostate Cancer Molecular Signature in Clinical Laboratory Improvement Amendments (CLIA) Environments. Cancers. 15. PMID 38136389 DOI: 10.3390/cancers15245843 |
0.161 |
|
| 2021 |
Nguyen H, Shah K, Waguespack SG, Hu MI, Habra MA, Cabanillas ME, Busaidy NL, Bassett R, Zhou S, Iyer PC, Simmons G, Kaya D, Pitteloud M, Subudhi SK, Diab A, et al. Immune checkpoint inhibitor related hypophysitis: diagnostic criteria and recovery patterns. Endocrine-Related Cancer. PMID 33890870 DOI: 10.1530/ERC-20-0513 |
0.157 |
|
| 2015 |
Sabharwal R, Verma P, Syed MA, Sharma T, Subudhi SK, Mohanty S, Gupta S. Emergence of micronuclei as a genomic biomarker. Indian Journal of Medical and Paediatric Oncology : Official Journal of Indian Society of Medical & Paediatric Oncology. 36: 212-8. PMID 26811590 DOI: 10.4103/0971-5851.171541 |
0.134 |
|
| 2016 |
Sinha M, Krishnappa P, Subudhi SK, Krishnamoorthy V. Supracostal percutaneous nephrolithotomy: A prospective comparative study. Indian Journal of Urology : Iju : Journal of the Urological Society of India. 32: 45-9. PMID 26941494 DOI: 10.4103/0970-1591.173121 |
0.077 |
|
| 2010 |
Subudhi SK, Callahan MK, Wolchok JD. Improving the therapeutic benefits of ipilimumab. Oncology (Williston Park, N.Y.). 24: 1288, 1294. PMID 21294472 |
0.068 |
|
| 2015 |
Malhotra G, Kataria P, Shukla P, Gupta S, Sargaiyan V, Mahendra A, Subudhi SK. A novel approach for retreatment of multirooted tooth by partial radisection. Annals of African Medicine. 14: 69-72. PMID 25567700 DOI: 10.4103/1596-3519.148751 |
0.066 |
|
| 1997 |
McKenzie SE, Subudhi SK, Cassel DL, Malladi P, Surrey S, Schwartz E. #644 c-kit gene promoter region polymorphism in a family with congenital hypoplastic anemia Journal of Pediatric Hematology/Oncology. 19: 383. DOI: 10.1097/00043426-199707000-00092 |
0.032 |
|
| 2015 |
Pattnaik S, Swain K, Rao JV, Varun T, Prusty KB, Subudhi SK. Aceclofenac nanocrystals for improved dissolution: Influence of polymeric stabilizers Rsc Advances. 5: 91960-91965. DOI: 10.1039/c5ra20411a |
0.028 |
|
| 2015 |
Pattnaik S, Swain K, Manaswini P, Divyavani E, Rao JV, Talla V, Subudhi SK. Fabrication of aceclofenac nanocrystals for improved dissolution: Process optimization and physicochemical characterization Journal of Drug Delivery Science and Technology. 29: 199-209. DOI: 10.1016/j.jddst.2015.07.021 |
0.015 |
|
| 2015 |
Pattnaik S, Swain K, Rao JV, Talla V, Prusty KB, Subudhi SK. Polymer co-processing of ibuprofen through compaction for improved oral absorption Rsc Advances. 5: 74720-74725. DOI: 10.1039/c5ra13038g |
0.01 |
|
| Hide low-probability matches. |